| Active group | Placebo group | P value (Mann Whitney) |
---|---|---|---|
FEV1 | 0.77 | 0.80 | 0.84 |
Pre-treatment | 0.77 (0.65–0.89) | 0.78 (0.61–0.95) |  |
FEV1 | 0.75 | 0.73 | 0.74 |
Post nebulized saline | 0.73 (0.62–0.84) | 0.75 (0.59–0.91) |  |
FEV1 | 0.80 | 0.77 | 0.63 |
Post salbutamol MDI | 0.81 (0.67–0.94) | 0.79 (0.62–0.96) |  |
Breathlessness | 4 | 4 | 0.34 |
Score 1 (Pre-treatment). | 3.9 (3.6–4.3) (1 = Not breathless, 7 = Worst possible breathlessness) | 3.5 (3.0–4.0) |  |
Breathlessness | 3 | 4 | Â |
Score 2 (Post nebulized saline) | 3.0 (2.6–3.5) | 3.3 (2.8–3.9) | 0.85 |
Wilcoxon test Score 1 V Score 2 | <0.0001 | 0.37 | Â |
Breathlessness | 3 | 3 | 0.35 |
Score 3 (Post salbutamol MDI) | 2.9 (2.5–3.3) | 3.0 (2.6–3.5) |  |
Wilcoxon test Score 2 V Score 3 | 0.43 | 0.014 | Â |
Symptom Relief | 3 | 1 | 0.0002 |
Score Post nebulized saline | 3.1 (2.7–3.6) (1 = No benefit, 7 = Best possible benefit) | 1.7 (1.2–2.3) |  |
Symptom Relief | 3 | 3 | 0.37 |
Score Post salbutamol MDI | 3.2 (2.7–3.7) | 2.9 (2.4–3.4) |  |